Victoria M. Ettorre, DO, MS
Clinical AssociateAbout
Research
Publications
2026
Whole-Exome Sequencing Identifies Candidate Genomic Features Associated with Response to Platinum-Based Chemotherapy and Ixabepilone-Based Treatment in Ovarian Cancer
Hartwich T, Bellone S, De Tommasi O, Ottum S, Ettorre V, Greenman M, Sethi N, Demirkiran C, Yang K, Abbasi A, Alexandrov L, Santin A. Whole-Exome Sequencing Identifies Candidate Genomic Features Associated with Response to Platinum-Based Chemotherapy and Ixabepilone-Based Treatment in Ovarian Cancer. International Journal Of Molecular Sciences 2026, 27: 7524. PMID: 42737428, PMCID: PMC13565503, DOI: 10.3390/ijms27177524.Peer-Reviewed Original ResearchIntegrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes
De Tommasi O, Palmieri L, Bellone S, Buza N, Sethi N, Ottum S, Demirkiran C, Hui P, Sun T, Niu N, Ettorre V, Hartwich T, Tozzi R, Santin A. Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes. Gynecologic Oncology 2026, 212: 72-79. PMID: 42567118, DOI: 10.1016/j.ygyno.2026.08.002.Peer-Reviewed Original ResearchPreclinical in vitro and in vivo activity of trastuzumab deruxtecan against ERBB2-mutated cervical carcinomas with low HER2 expression
Sethi N, Ottum S, Bellone S, Demirkiran C, Buza N, Hui P, De Tommasi O, Palmieri L, Ettorre V, Greenman M, Hartwich T, Ratner E, Santin A. Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against ERBB2-mutated cervical carcinomas with low HER2 expression. Gynecologic Oncology Reports 2026, 66: 102171. PMID: 42500114, PMCID: PMC13396741, DOI: 10.1016/j.gore.2026.102171.Peer-Reviewed Original ResearchPreclinical activity of tisotumab vedotin, an antibody–drug conjugate targeting tissue factor, in uterine serous carcinoma
Ottum S, Sethi N, Bellone S, Demirkiran C, Buza N, Hui P, Palmieri L, De Tommasi O, Ettorre V, Greenman M, Hartwich T, Ratner E, Santin A. Preclinical activity of tisotumab vedotin, an antibody–drug conjugate targeting tissue factor, in uterine serous carcinoma. Gynecologic Oncology 2026, 211: 191-199. PMID: 42456482, DOI: 10.1016/j.ygyno.2026.07.007.Peer-Reviewed Original ResearchA Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer
Santin A, Roque D, Siegel E, Ettorre V, Greenman M, McNamara B, Papatla K, Kailasam A, Buza N, Clark M, Hui P, Dottino P, Ratner E, Bellone S. A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer. Clinical Cancer Research 2026, 32: 3169-3178. PMID: 42132892, PMCID: PMC13430211, DOI: 10.1158/1078-0432.ccr-26-0144.Peer-Reviewed Original ResearchThis study investigates sacituzumab govitecan, a Trop-2–targeted drug, showing 28% response in recurrent endometrial cancer and manageable safety in heavily pretreated patients.Response to Wu et al. regarding “Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models”
Ettorre V, Buza N, Palmieri L, Santin A. Response to Wu et al. regarding “Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models”. International Journal Of Gynecological Cancer 2026, 104632. PMID: 41946648, DOI: 10.1016/j.ijgc.2026.104632.Commentaries, Editorials and LettersRemarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts
Palmieri L, Bellone S, Demirkiran C, Hartwich T, Sethi N, Ettorre V, Ottum S, Greenman M, Buza N, Hui P, Perrone E, Fanfani F, Fagotti A, Ratner E, Santin A. Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts. Gynecologic Oncology 2026, 206: 65-73. PMID: 41690203, DOI: 10.1016/j.ygyno.2026.02.004.Peer-Reviewed Original ResearchIntegrated mutational landscape analysis of endometrial stromal sarcoma
Hartwich T, Choi S, Hwang A, Bellone S, Palmieri L, Seo H, Kim T, Hong J, Krakstad C, Trovik J, Stefansson I, Haugland H, Greenman M, Ettorre V, Ottum S, Demirkiran C, Yang-Hartwich Y, Buza N, Hui P, Lopez S, Cormio G, Ramunno M, Zito A, Perrone E, Fagotti A, Fanfani F, Santoro A, Ravaggi A, Bignotti E, Odicino F, Ardighieri L, Ratner E, Angioli R, Perrone G, Luvero D, Conca B, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of endometrial stromal sarcoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2026, 123: e2531105123. PMID: 41591910, PMCID: PMC12867622, DOI: 10.1073/pnas.2531105123.Peer-Reviewed Original Research
2025
Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma − A case report
Ettorre V, Palmieri L, Ottum S, Greenman M, Santin A. Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma − A case report. Gynecologic Oncology Reports 2025, 63: 102011. PMID: 41561674, PMCID: PMC12813050, DOI: 10.1016/j.gore.2025.102011.Peer-Reviewed Original ResearchFolate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models
Ettorre V, Conca B, Demirkiran C, Bellone S, Sethi N, Hartwich T, Niu N, Buza N, Angioli R, Plotti F, Palmieri L, Santin A. Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models. International Journal Of Gynecological Cancer 2025, 36: 102779. PMID: 41411700, DOI: 10.1016/j.ijgc.2025.102779.Peer-Reviewed Original Research